GBT
INSY

Grove Bank & Trust’s Insys Therapeutics, Inc. INSY Stock Holding History

Grove Bank & Trust’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-200
Closed -$3K – 277
2016
Q2 		$3K Hold
200
– – ﹤0.01% 258
2016
Q1 		$3K Hold
200
– – ﹤0.01% 254
2015
Q4 		$6K Buy
+200
New +$5.54K 0.01% 298

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Grove Bank & Trust's INSY Position: Q3 2016 in Review

Grove Bank & Trust sold out of Insys Therapeutics, Inc. (INSY) in Q3 2016, closing a stake of 200 shares — an estimated $3K sold.

Grove Bank & Trust first reported a position in INSY in Q4 2015 and held it in 3 quarters. The position peaked at $6K in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q3 2016.

  • Grove Bank & Trust reported no remaining Insys Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Grove Bank & Trust sold 200 Insys Therapeutics, Inc. shares in Q3 2016, an estimated $3K.
  • Grove Bank & Trust first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
  • Grove Bank & Trust's Insys Therapeutics, Inc. position peaked at $6K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2016.

Based on Grove Bank & Trust's 13F filing for Q3 2016, filed 4 Nov 2016.